RS20050832A - Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti - Google Patents

Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti

Info

Publication number
RS20050832A
RS20050832A YUP-2005/0832A YUP20050832A RS20050832A RS 20050832 A RS20050832 A RS 20050832A YU P20050832 A YUP20050832 A YU P20050832A RS 20050832 A RS20050832 A RS 20050832A
Authority
RS
Serbia
Prior art keywords
hydrogen
aliphatic
compounds
ring
halo
Prior art date
Application number
YUP-2005/0832A
Other languages
English (en)
Serbian (sr)
Inventor
Michael Hepperle
Julie Fields Liu
Francois Soucy
Yingchun Ye
Robert Murray
Raman Prakash
Jeremy Little
Alfredo Castro
Hormoz Mazdiyasni
Paul Fleming
Dominic Reynolds
Original Assignee
Millennium Pharmaceuticals Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc., filed Critical Millennium Pharmaceuticals Inc.,
Publication of RS20050832A publication Critical patent/RS20050832A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
YUP-2005/0832A 2003-04-09 2004-04-09 Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti RS20050832A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09
PCT/US2004/011080 WO2004092167A1 (en) 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease

Publications (1)

Publication Number Publication Date
RS20050832A true RS20050832A (sr) 2007-12-31

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0832A RS20050832A (sr) 2003-04-09 2004-04-09 Beta-karbolini koji su korisni u tretiranju inflamatornih bolesti

Country Status (22)

Country Link
US (2) US7727985B2 (enExample)
EP (1) EP1611134A1 (enExample)
JP (1) JP2006522824A (enExample)
KR (1) KR20060006031A (enExample)
CN (1) CN1802375A (enExample)
AU (1) AU2004230952A1 (enExample)
BR (1) BRPI0409263A (enExample)
CA (1) CA2521300A1 (enExample)
CO (1) CO5700746A2 (enExample)
CR (1) CR8042A (enExample)
EA (1) EA009121B1 (enExample)
EC (1) ECSP056145A (enExample)
HR (1) HRP20050926A2 (enExample)
MA (1) MA27837A1 (enExample)
MX (1) MXPA05010793A (enExample)
NI (1) NI200500174A (enExample)
NO (1) NO20054598L (enExample)
OA (1) OA13115A (enExample)
RS (1) RS20050832A (enExample)
TN (1) TNSN05257A1 (enExample)
WO (1) WO2004092167A1 (enExample)
ZA (1) ZA200508198B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522824A (ja) 2003-04-09 2006-10-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患を処置するために有用なβ−カルボリン
BRPI0509660A (pt) * 2004-04-09 2007-10-09 Millennium Pharm Inc compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006316322B2 (en) * 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
US8426355B2 (en) * 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
AU2007334541A1 (en) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates as mutual prodrugs of anti-inflammatory signal transduction modulators (AISTM's) and beta-agonists for the treatment of pulmonary inflammation and bronchoconstriction
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
EP2297347B1 (en) 2008-05-14 2017-03-08 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
US9440966B2 (en) * 2011-03-28 2016-09-13 Sjt Molecular Research, S.L. Compounds for treatment of metabolic syndrome
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297908T1 (de) * 1998-08-12 2005-07-15 Pfizer Prod Inc Tace inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
MXPA02007981A (es) 2000-03-15 2004-04-05 Aventis Pharma Gmbh Beta-carbolinas sustituidas con actividad que inhibe la ikb-cinasa.
BR0212617A (pt) * 2001-09-19 2005-02-09 Pharmacia Corp Compostos de pirazolila substituìdo para o tratamento de inflamação
AU2002352498A1 (en) * 2001-11-07 2003-05-19 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
WO2004080996A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
JP2006522824A (ja) 2003-04-09 2006-10-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患を処置するために有用なβ−カルボリン

Also Published As

Publication number Publication date
WO2004092167A1 (en) 2004-10-28
OA13115A (en) 2006-11-10
HRP20050926A2 (en) 2006-06-30
AU2004230952A1 (en) 2004-10-28
NO20054598L (no) 2005-10-27
MXPA05010793A (es) 2005-12-05
US20100093713A1 (en) 2010-04-15
ECSP056145A (es) 2006-04-19
EP1611134A1 (en) 2006-01-04
US20040235839A1 (en) 2004-11-25
ZA200508198B (en) 2007-01-31
EA200501584A1 (ru) 2006-06-30
MA27837A1 (fr) 2006-04-03
WO2004092167A8 (en) 2006-01-05
JP2006522824A (ja) 2006-10-05
EA009121B1 (ru) 2007-10-26
CO5700746A2 (es) 2006-11-30
US7727985B2 (en) 2010-06-01
CR8042A (es) 2006-05-30
TNSN05257A1 (en) 2007-07-10
KR20060006031A (ko) 2006-01-18
CN1802375A (zh) 2006-07-12
BRPI0409263A (pt) 2006-03-28
NI200500174A (es) 2006-04-17
NO20054598D0 (no) 2005-10-06
CA2521300A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
US20100093713A1 (en) Beta-carbolines useful for treating inflammatory disease
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
AU2017304761B2 (en) Pharmaceutical compounds
TW202344505A (zh) 作為parp7抑制劑的嗒𠯤酮
EP3710443A1 (en) Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
AU2017239481A1 (en) DNA-PK inhibitors
JP2021512158A (ja) Ｒｈｏ関連プロテインキナーゼのモジュレーター
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
US7951801B2 (en) Beta-carbolines useful for treating inflammatory disease
MX2013009767A (es) Compuestos y composiciones como inhibidores de trk.
NZ749946A (en) Novel compound or pharmaceutically acceptable salt thereof
JP6559699B2 (ja) 置換含窒素複素環誘導体、それを含む医薬組成物及びその抗腫瘍性の適用
JP2011518127A (ja) ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
US20050245563A1 (en) Chk-1 inhibitors
JP2023540548A (ja) 抗腫瘍活性を有する化合物及びその使用
CA3121376A1 (en) Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
WO2005118583A1 (en) 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2023545065A (ja) オートタキシン抑制剤化合物
WO2009067233A1 (en) Beta carbolines and uses thereof
JP2013523806A (ja) スルタム化合物
HK40083035A (en) Parp7 inhibitor and use thereof